Skip to main content

FDA warning letter: iRhythm committed multiple violations, failed to report patient deaths in time

By Cardiovascular Business  
   June 08, 2023

The U.S. Food and Drug Administration (FDA) sent a warning letter to iRhythm Technologies detailing several issues related to the company’s Zio AT mobile cardiac telemetry device.

Full story

Get the latest on healthcare leadership in your inbox.